NEW YORK (GenomeWeb) – Biodesix has signed an agreement making Mumbai-based Positive Bioscience a distributor of its liquid biopsy tests for non-small cell lung cancer in India, the companies announced today.
Under the terms of the deal, Positive will offer Biodesix's GeneStrat and VeriStrat in India. All testing will be performed at Biodesix's laboratory in Boulder, Colorado. Additional terms were not disclosed.
GeneStrat measures circulating tumor DNA and RNA in blood to find KRAS and BRAF mutations; EGFR sensitization and resistance; and EML4-ALK, ROS1, and RET fusion variants. VeriStrat is a blood-based, proteomic test offering prediction and prognosis for patients with NSCLC.
"Our centralized testing approach enables rapid and high-quality test results within four days for Indian patients, well in advance of the 10 [to]14 day average turnaround time for tissue-based testing," Biodesix CEO David Brunel said in a statement.
Earlier this year, Biodesix formed a Chinese commercialization partnership for VeriStrat with Bioyong Industries and an Israeli distribution alliance for VeriStrat and GeneStrat with Progenetics.